A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population.
Four hundred and twenty children were randomly assigned to receive either mumps measles rubella (MMR) vaccine (207) or measles vaccine (213) in a single blind study, to investigate the reactogenicity and serology of the MMR vaccine. There was no significant difference between the number of children developing symptoms after MMR vaccination to those developing symptoms after measles vaccination. Both vaccines are associated with a rash, temperature and restlessness five to thirteen days after vaccination. The serological response to measles vaccine was similar in both groups with 92-6% seroconverting with MMR, and 96-8% with measles. Seroconvertion against mumps and rubella with the MMR vaccine was 88% and 96% respectively. This study confirms the safety and efficacy of the MMR vaccine in a UK population.
Edees
S
S
Department of Child Health, University Hospital, Queen's Medical Centre, Nottingham.
Pullan
C R
CR
Hull
D
D
D004338:Drug Combinations; D006801:Humans; D007223:Infant; D008458:Measles Vaccine / Q000009:adverse effects* / Q000097:blood / Q000276:immunology; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine / Q000009:adverse effects* / Q000097:blood / Q000276:immunology; D011897:Random Allocation; D012411:Rubella Vaccine / Q000009:adverse effects* / Q000097:blood / Q000276:immunology; D006113:United Kingdom
D004338:Drug Combinations; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine